Congenital adrenal hyperplasia market forecast to reach $0.69B by 2030
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Changes In Market Value Are Expected For The Congenital Adrenal Hyperplasia Market Over The 2026–2030 Period?
The congenital adrenal hyperplasia market has seen substantial growth recently. Its value is anticipated to rise from $0.5 billion in 2025 to $0.53 billion in 2026, progressing at a compound annual growth rate (CAGR) of 7.1%. This historical expansion can be linked to several factors including limited options for enzyme replacement, the necessity of lifelong glucocorticoid therapy, inadequate awareness in emerging regions, delayed diagnoses resulting from a lack of screening, and a reliance on hospital-based endocrinology care.
The market for congenital adrenal hyperplasia is projected to experience robust expansion over the coming years. This market is anticipated to reach a valuation of $0.7 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.8%. The upward trend during the forecast period can be primarily attributed to progress in precision medicine techniques, wider availability of genetic testing, rising spending on healthcare, the proliferation of specialized clinics, and enhanced patient compliance due to innovative drug formulations. Key developments expected within this period involve broadened newborn screening initiatives, the introduction of long-acting and modified-release steroid treatments, more effective mineralocorticoid and androgen suppression protocols, a growing embrace of multidisciplinary care frameworks, and an intensified emphasis on managing the disease throughout a patient’s life.
Access Your Free Sample Report For In-Depth Market Analysis:
What Key Factors Are Affecting The Congenital Adrenal Hyperplasia Market Demand?
The increasing requirement for gene therapy is anticipated to drive expansion within the congenital adrenal hyperplasia market moving forward. Gene therapy describes a medical approach centered on altering or manipulating a person’s genes to address or avert illnesses. This growing need for gene therapy stems from progress in genetic research and biotechnology, allowing for more accurate and specific treatments for genetic conditions, malignancies, and other persistent ailments. Congenital adrenal hyperplasia (CAH), a condition arising from gene mutations affecting adrenal hormone creation, is a key area for gene therapy, presenting chances for specific genetic interventions to mend fundamental genetic flaws and reinstate proper hormone activity. As an illustration, in April 2024, the American Society of Gene and Cell Therapy (ASGCT), a professional membership organization based in the US, reported that out of 1,023 gene therapies under development for rare diseases, eight of the top 10 were oncological. Additionally, the second quarter of 2024 marked the commencement of 76 gene therapy trials, signifying a 25% rise compared to the preceding quarter. Consequently, the increased demand for gene therapy is fostering expansion in the congenital adrenal hyperplasia market.
Which Segment Classifications Are Used In The Congenital Adrenal Hyperplasia Market Segment Analysis?
The congenital adrenal hyperplasia market covered in this report is segmented –
1) By Type: Classic Congenital Adrenal Hyperplasia, Non-Classic Congenital Adrenal Hyperplasia
2) By Treatment And Diagnosis: Diagnosis, Treatment
3) By End-Use: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Research Institutes
Subsegments:
1) By Classic Congenital Adrenal Hyperplasia: Salt-Wasting Classic Congenital Adrenal Hyperplasia, Simple Virilizing Classic Congenital Adrenal Hyperplasia
2) By Non-Classic Congenital Adrenal Hyperplasia: Late-Onset Non-Classic Congenital Adrenal Hyperplasia, Mild Non-Classic Congenital Adrenal Hyperplasia
What Trends Are Influencing Changes In The Congenital Adrenal Hyperplasia Market?
Leading companies in the congenital adrenal hyperplasia market are dedicated to developing innovative treatments, such as CRF1 receptor antagonists, aimed at regulating cortisol production and reducing excessive adrenal androgens. A CRF1 receptor antagonist is a medication that inhibits the corticotropin-releasing factor 1 (CRF1) receptor to modulate the body’s stress response and diminish surplus adrenal androgen production in conditions like congenital adrenal hyperplasia. For instance, in December 2024, Neurocrine Biosciences, Inc., a biopharmaceutical company based in the US, secured FDA approval for crenessity (crinecerfont), which is the first new treatment for congenital adrenal hyperplasia (CAH) in 70 years. This oral drug functions as a selective antagonist of corticotropin-releasing factor type 1 receptors, thereby helping to manage elevated adrenocorticotropic hormone (ACTH) and adrenal androgens while enabling a reduction in glucocorticoid doses. The approval was supported by data from the CAHtalyst Phase 3 studies, which confirmed significant efficacy in decreasing androgen levels. Crenessity is expected to become available soon, signifying a major progression in CAH management.
Which Firms Are Contributing To The Congenital Adrenal Hyperplasia Market Ecosystem?
Major companies operating in the congenital adrenal hyperplasia market are Pfizer Inc., Sanofi S.A., Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Eton Pharmaceuticals Inc, Teva Pharmaceutical Industries, Macleods Pharmaceuticals, H. Lundbeck A/S, Neurocrine Biosciences Inc., BridgeBio Pharma Inc, Regenxbio Inc., Millendo Therapeutics Inc., Applied Therapeutics, Inc., OMass Therapeutics Limited, ViennaLab Diagnostics GmbH, EffRx Pharmaceuticals SA, Adrenas Therapeutics Inc, HBM Alpha Therapeutics, Spruce Biosciences Inc., Crinetics Pharmaceuticals Inc.
Get The Full Congenital Adrenal Hyperplasia Market Report:
Which Region Dominates The Congenital Adrenal Hyperplasia Market By Market Share?
North America was the largest region in the congenital adrenal hyperplasia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the congenital adrenal hyperplasia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Congenital Adrenal Hyperplasia Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Congenital Adrenal Hyperplasia Market 2026, By The Business Research Company
Pituitary Dwarf Treatment Market Report 2026
https://www.thebusinessresearchcompany.com/report/pituitary-dwarf-treatment-global-market-report
Congenital Heart Disease Chd Market Report 2026
https://www.thebusinessresearchcompany.com/report/congenital-heart-disease-chd-global-market-report
Pheochromocytoma Market Report 2026
https://www.thebusinessresearchcompany.com/report/pheochromocytoma-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
